Ronald Ramos

Assistant Professor

McMaster University

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ronald Ramos is an Assistant Professor at McMaster University in Canada. His research primarily focuses on neuro-oncology, particularly in the areas of glioma classification, treatment trends, and patient outcomes related to brain tumors. His recent publications include studies on therapies for glioblastoma, medulloblastoma, and various treatments for associated symptoms in patients with neurofibromatosis and other conditions.

Articles (9)

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (4)

Lori Bernstein

Assistant Professor, Status Only

University of Toronto

CANADA

View details

Paola Jablonska

Clinica Universidad de Navarra

SPAIN

View details

Normand Laperriere

Professor

University of Toronto

CANADA

View details

Kim Edelstein

University of Toronto

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ronald Ramos

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma

Trametinib for Painful Glomus Tumors in a Patient with Neurofibromatosis Type 1

Bevacizumab for Cerebral Radionecrosis: A Single-Center Experience

Review of 20 years of Adult Medulloblastoma Treatment at a High-Volume Center – Chemotherapy Prescription Trends and Survival

Review of 20 years of adult medulloblastoma treatment: Chemotherapy prescription trends and survival

Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report

149: Review of 20 Years of Adult Medulloblastoma Treatment at a High-Volume Centre - Chemotherapy Prescription Trends and Survival

Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas.

Outcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis

Collaborators (4)

Lori Bernstein

Paola Jablonska

Normand Laperriere

Kim Edelstein

Make your next move.